Table 1 Characteristics of sequenced participants at enrollment.

From: Medically actionable pathogenic variants in a population of 13,131 healthy elderly individuals

 

ASPREE N = 13,131 (mean age 75 years)

Female sex: number (%)

7056 (54)

Age in years: number (%)

  70–74 years

7894 (60)

  75–79 years

3406 (26)

  ≥80 years

1831 (14)

Race or ethnic group:a number (%)

  White/Caucasian

12,953 (99)

  Other

178 (1)

 Obese (BMI ≥ 30 kg/m2)b (%)

28

 Current smoking (%)

4

 Heart, stroke, or vascular diseasec (%)

0

 Personal cancer history (%)

20

  Breast cancer history (%)

4

  Colorectal cancer history (%)

3

  1. Sequenced participants were enrolled in the ASPREE clinical trial, aged 70 years and older, without cardiovascular disease, dementia, physical disability, or life-threatening cancer diagnoses. Most were white/Caucasian and 54% were female. Participants with personal cancer history were not excluded, other than those with cancer diagnoses deemed likely to cause death within five years.
  2. ASPREE ASPirin in Reducing Events in the Elderly, BMI body mass index.
  3. aSelf-report.
  4. bObese was defined as body mass index (weight in kilograms divided by the square of the height in meters) of ≥30.
  5. cBaseline characteristics of participants in the ASPREE (ASPirin in Reducing Events in the Elderly) study.11
Back to article page